Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors

2020 ◽  
Vol 28 (12) ◽  
pp. 6159-6173
Author(s):  
Maria E. Suarez-Almazor ◽  
Xerxes Pundole ◽  
Noha Abdel-Wahab ◽  
Douglas B. Johnson ◽  
Dipti Gupta ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Supportive Care ◽  
Checkpoint Inhibitors ◽  
Practice Recommendations ◽  
Immune Mediated

Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors

2020 ◽  
Vol 28 (12) ◽  
pp. 6119-6128
Author(s):  
Jennifer Choi ◽  
Ronald Anderson ◽  
Ada Blidner ◽  
Tim Cooksley ◽  
Michael Dougan ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Supportive Care ◽  
Checkpoint Inhibitors ◽  
Practice Recommendations

scholarly journals Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity

2020 ◽  
Vol 28 (12) ◽  
pp. 6145-6157
Author(s):  
Vickie R. Shannon ◽  
Ronald Anderson ◽  
Ada Blidner ◽  
Jennifer Choi ◽  
Tim Cooksley ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Adverse Events ◽  
Supportive Care ◽  
Pulmonary Toxicity ◽  
Practice Recommendations

scholarly journals Immuno-related endocrinopathy in patients treated with immune checkpoint inhibitors

2020 ◽  
pp. 16-24
Author(s):  
D. I. Yudin ◽  
K. K. Laktionov ◽  
K. A. Sarantseva ◽  
O. I. Borisova ◽  
V. V. Breder ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Clinical Practice ◽  
Adverse Events ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Serious Adverse Events ◽  
Immune Mediated ◽  
Discontinuation Of Treatment ◽  
The Russian Federation

Recently immune checkpoint inhibitors amazingly changed the landscape of cancer therapy worldwide. The number of immune checkpoint molecules in clinical practice is constantly increasing. There are some monoclonal antibodies recently registered in the Russian Federation: anti-PD1 antibodies (nivolumab, pembrolizumab), anti-PD-L1 (atezolizumab, durvalumab), anti-CTLA-4 (ipilimumab). Immune-mediated endocrinopathies are some of the most common complications of immunotherapy. According to the results of clinical studies, the incidence of serious endocrine immuno-mediated adverse events with anti-PD1 monoclonal antibodies is low (3.5–8%). The use of anti-CTLA4 antibodies, combined regimens, and the use of immunotherapy after chemoradiotherapy significantly increase the incidence of serious adverse events to 30%. In clinical practice of N.N. Blokhin Cancer Research Center among 245 non-small cell lung cancer and hepatocellular carcinoma patients treated with immunotherapy, 22 (8,9%) developed an immune-mediated endocrinopathy. Most patients developed adverse events of 1–2 degrees, in two patients – 3 degrees, requiring discontinuation of treatment. The aim of this article was to provide useful information and recommendations regarding the management of common immuno-related endocrine adverse events (including hypothyroidism, hyperthyroidism, pituitary, adrenal insufficiency) for clinical oncologists.

Pathogenesis, Clinical Manifestations and Management of Immune Checkpoint Inhibitors Toxicity

2017 ◽  
Vol 103 (5) ◽  
pp. 405-421 ◽  
Author(s):  
Alessandro Inno ◽  
Giulio Metro ◽  
Paolo Bironzo ◽  
Antonio M. Grimaldi ◽  
Elisabetta Grego ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Adverse Events ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Clinical Manifestations ◽  
Know How ◽  
Immune Mediated ◽  
Medical Oncologists ◽  
Tumor Types

Immune checkpoint inhibitors have emerged as an effective treatment for several tumor types and their use in clinical practice is expected to further increase in the immediate future. Although these agents are well tolerated, they are associated with a peculiar spectrum of toxicity, which is immune mediated and may potentially affect every organ. However, immune-related adverse events are mostly reversible if promptly diagnosed and adequately treated. Therefore, it is crucial that medical oncologists know how to diagnose and treat immune-related adverse events. This review focuses on the pathogenesis, clinical manifestations and management of immune-related toxicity of anti-CTLA-4 and anti-PD-1 antibodies.

Current and Future Aspects of Immunotherapy for Esophageal and Gastric Malignancies

2019 ◽  
pp. 237-247 ◽  
Author(s):  
Ramon Andrade De Mello ◽  
Florian Lordick ◽  
Kei Muro ◽  
Yelena Y. Janjigian
Keyword(s):  
Clinical Practice ◽  
Checkpoint Inhibitors ◽  
Predictive Biomarkers ◽  
The United States ◽  
Biologic Agents ◽  
Antitumor Effects ◽  
Asian Populations ◽  
Immune Mediated ◽  
Novel Biomarkers ◽  
Geographic Differences

Esophagogastric (EG) cancer has a poor prognosis despite the use of standard therapies, such as chemotherapy and biologic agents. Recently, immune checkpoint inhibitors (ICIs) have been introduced as treatments for EG cancer; nivolumab and pembrolizumab have been approved in the United States and Europe to treat advanced EG cancer. Other ICIs, such as avelumab, durvalumab, ipilimumab, and tremelimumab, have been evaluated in several trials, although their roles are still not established in clinical practice. In addition, preclinical evidence suggests that combining an ICI with a tumor-targeting antibody can result in greater antitumor effects in metastatic EG cancer. There are not yet validated predictive biomarkers to identify which patients will respond best to ICI treatment. PD-L1 expression may predict intensity of response, although PD-L1–negative patients can still respond to ICIs. Despite differences in PD-L1 expression between Asian and non-Asian populations, no geographic differences in rates of treatment-related or immune-mediated/infusion-related adverse events have been reported. Also, several trials are currently evaluating combinations of ICIs, standard chemotherapy, and biologic agents as well as novel biomarkers to improve treatments and outcomes. Our review will address the current use of and evidence for ICIs for advanced EG cancer treatment and future trends in this area for clinical practice.

scholarly journals ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma

2021 ◽  
Author(s):  
Pashna N. Munshi ◽  
Mehdi Hamadani ◽  
Ambuj Kumar ◽  
Peter Dreger ◽  
Jonathan W. Friedberg ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
Cellular Therapies ◽  
Practice Recommendations ◽  
Mantle Cell
Sign in / Sign up

Export Citation Format

Share Document